The 13 references in paper I. Kozhanova N., I. Romanova S., L. Gavrilenko N., A. Patseev V., M. Sachek M., И. Кожанова Н., И. Романова С., Л. Гавриленко Н., А. Пацеев В., М. Сачек М. (2015) “Экономическая и клиническая оценка применения ивабрадина при стабильной стенокардии в системе здравоохранения Республики Беларусь // CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM” / spz:neicon:pharmacoeconomics:y:2014:i:2:p:38-43

1
State statistical reports. Approved by the Resolution of the National Statistics Committee of Belarus 11.08.2010 No 165. 2011. (In Russ.).
(check this in PDF content)
2
Zyryanov S.K., Belousov Yu.B. ABC / VEN-analysis [Teaching aid. ABC/VEN-analiz. Uchebno-metodicheskoe posobie]. Moscow. 2004.
(check this in PDF content)
3
Instructions for use «Pharmacoeconomic rationale for the use of drugs with proven efficacy for the treatment of patients with chronic diseases in terms of practical health care.» Approved by the Ministry of Health, registration number 041-0508, 2008 (In Russ.).
(check this in PDF content)
4
Clinical and economic analysis (evaluation, selection of medical technology and quality control of medical care). PA Vorobyev, MV Avksentiev AS Yuriev, MV Sura (ed). [Kliniko-ekonomicheskii analiz (otsenka, vybor meditsinskikh tekhnologii i upravlenie kachestvom meditsinskoi pomoshchi) / P.A. Vorob'ev, M.V. Avksent'eva, A.S. Yur'ev, M.V. Sura]. Moscow. 2004; 404 s.
(check this in PDF content)
5
Mrochek A.G. i dr. Kardiologiya v Belarusi. 2012; 5: 99-112.
(check this in PDF content)
6
CHOosing Interventions that are Cost Effective (WHO-CHOICE). Mode of access: http://www.who.int/choice/costs/CER_thresholds/en/ index.html
(check this in PDF content)
7
Fox K. et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart. J. 2009; 30 (19): 2337-45.
(check this in PDF content)
8
Holmes D. et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation. 1986; 73: 1254-1263.
(check this in PDF content)
9
Jorge F. Cost-effectiveness analysis of Procoralan® (ivabradine) for symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers. ExigoConsultores for Servier.
(check this in PDF content)
10
Matthew T. et al. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health and Quality of Life Outcomes. Mode of access: http:// www.hqlo.com/content/8/1/13.
(check this in PDF content)
11
Mortality Country Sheet 2006: Great Britain, France, Germany, Poland, Belarus, Russian Federation. 2007. Mode of access: http:// www. who.com/WHO Global InfoBase Online/International Comparisons.
(check this in PDF content)
12
Pepine C. et al. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290: 2805-2816.
(check this in PDF content)
13
Rambihar S. et al. Heart Rate is associated with Increased Risk of Major Cardiovascular Events, Cardiovascular and All-Cause Death in Patients with Stable Chronic Cardiovascular Disease – An Analysis of ONTARGET/ TRANSCEND. Circulation. 2010; 122: A12677. CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC
(check this in PDF content)